Human umbilical cord mesenchymal stem cells derived exosomes exert antiapoptosis effect via activating PI3K/Akt/mTOR pathway on H9C2 cells

被引:61
|
作者
Liu, Hui [1 ]
Sun, Xiaolu [1 ]
Gong, Xuhe [2 ]
Wang, Guogan [1 ]
机构
[1] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Dept Cardiol, Lab Cardiovasc Dis,Fuwai Hosp, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Dept Cardiol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
apoptosis; autophagy; exosomes; PI3K/Akt/mTOR pathway; umbilical cord mesenchymal stem cells; CLINICAL-TRIAL; HEART-FAILURE; APOPTOSIS; THERAPY; AUTOPHAGY; HYPOXIA; AKT; DYSFUNCTION; MECHANISMS; SURVIVAL;
D O I
10.1002/jcb.28705
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background/Objectives In recent years, as an alternative to stem cell therapy for cardiovascular diseases (CVD), exsomes have attracted wide attention among researchers. The present study aimed to investigate the role of human umbilical cord mesenchymal stem cells (UC-MSCs) derived exosomes play on H9C2 cells apoptosis and possible mechanisms. Methods Exosomes were isolated from normal UC-MSCs culture media and hypoxic preconditioning culture media. Transmission electron microscopy was used to observe the morphology of exosomes. Nanoparticle tracking analysis was used to detect the size distribution and concentration of exosomes. Western blot analysis was used to analyzed the surface marker CD63 of exosomes. H9C2 cells were induced apoptosis by hypoxia and serum deprivation (H/SD) and then were treated respectively by group. Cell Counting Kit-8 assay was used to detect viability of H9C2 cells. Apoptosis was detected by Hochest staining and annexin V-FITC/PI. The expression levels of related proteins of apoptosis, autophagy, and PI3K/Akt/mTOR pathway were analyzed by Western blot analysis. Immunofluorescence was used to analyze LC3B expression. Results Hypoxic preconditioning increased the exosomes secretion of UC-MSCs. UC-MSCs derived exosomes could inhibit H/SD-induced H9C2 cells apoptosis. Hypoxic preconditioning strengthened this antiapoptosis effect of UC-MSCs. Hypoxic preconditioning UC-MSCs derived exosomes (H-Exo) downregulated LC3B-II/I and beclin-1 and upregulated P62, p-Akt/Akt and p-mTOR/mTOR. The antiapoptotic effect of H-Exo could be attenuated by treatment with LY294002 and rapamycin. Conclusion UC-MSCs derived exosomes could inhibit H9C2 cells apoptosis induced by H/SD through regulating autophagy via PI3K/Akt/mTOR pathway. Hypoxia preconditioning could enhance above effects through increasing exosomes secretion of UC-MSCs.
引用
收藏
页码:14455 / 14464
页数:10
相关论文
共 50 条
  • [31] Columbianadin Ameliorates Myocardial Injury by Inhibiting Autophagy Through the PI3K/Akt/mTOR Signaling Pathway in AMI Mice and Hypoxic H9c2 Cells
    Niu, Zi-Chang
    An, Ran
    Shi, Hui-hui
    Jin, Qi
    Song, Jun-li
    Chang, Yan-xu
    Li, Yu-Hong
    Fu, Shu-fei
    Mao, Hao-ping
    PHYTOTHERAPY RESEARCH, 2025, 39 (01) : 521 - 535
  • [32] Integrin β1 in Adipose-Derived Stem Cells Accelerates Wound Healing via Activating PI3K/AKT Pathway
    Qihong Wang
    Na Zhang
    Lihua Hu
    Yong Xi
    Wenxin Mi
    Yindong Ma
    Tissue Engineering and Regenerative Medicine, 2020, 17 : 183 - 192
  • [33] Exosomes derived from human umbilical cord mesenchymal stem cells promote osteogenesis through the AKT signaling pathway in postmenopausal osteoporosis
    Ren, Shi-Wei
    Cao, Guang-Qing
    Zhu, Qing-Run
    He, Min-Gang
    Wu, Fang
    Kong, Su-Mei
    Zhang, Zhao-Yan
    Wang, Qiang
    Wang, Feng
    AGING-US, 2022, 14 (24): : 10125 - 10136
  • [34] Human umbilical vein endothelial cells-derived exosomes enhance cardiac function after acute myocardial infarction by activating the PI3K/AKT signaling pathway
    Liu, Wei
    Feng, Yu
    Wang, Xuehua
    Ding, Jiaxing
    Li, Huili
    Guan, Hongquan
    Chen, Zhijian
    BIOENGINEERED, 2022, 13 (04) : 8850 - 8865
  • [35] HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway
    Xu, Ling
    Xing, Qu
    Huang, Tuanjie
    Zhou, Jiankang
    Liu, Tengfei
    Cui, Yuanbo
    Cheng, Tian
    Wang, Yaping
    Zhou, Xinkui
    Yang, Bo
    Yang, Greta Luyuan
    Zhang, Jiewen
    Zang, Xingxing
    Ma, Shanshan
    Guan, Fangxia
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2019, 12
  • [36] Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote the Proliferation of Schwann Cells by Regulating the PI3K/AKT Signaling Pathway via Transferring miR-21
    Ma, Yongbin
    Zhou, Dan
    Zhang, Huanyan
    Tang, Liming
    Qian, Fen
    Su, Jianhua
    STEM CELLS INTERNATIONAL, 2021, 2021
  • [37] Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) alleviate excessive autophagy of ovarian granular cells through VEGFA/PI3K/AKT/mTOR pathway in premature ovarian failure rat model
    Dai, Wenjie
    Yang, Hong
    Xu, Bo
    He, Tiantian
    Liu, Ling
    Ma, Xiaoqian
    Ma, Jiaxue
    Yang, Guoqin
    Si, Rui
    Pei, Xiuying
    Du, Xing
    Fu, Xufeng
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [38] Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) alleviate excessive autophagy of ovarian granular cells through VEGFA/PI3K/AKT/mTOR pathway in premature ovarian failure rat model
    Wenjie Dai
    Hong Yang
    Bo Xu
    Tiantian He
    Ling Liu
    Xiaoqian Ma
    Jiaxue Ma
    Guoqin Yang
    Rui Si
    Xiuying Pei
    Xing Du
    Xufeng Fu
    Journal of Ovarian Research, 16
  • [39] Human umbilical cord-derived mesenchymal stem cells improve chronic pancreatitis in rats via the AKT-mTOR-S6K1 signaling pathway
    Kong, Lijun
    Xu, Xiangxiang
    Zhang, Hewei
    Zhou, Yi
    Huang, Hongjian
    Chen, Bicheng
    Zhou, Zhenxu
    BIOENGINEERED, 2021, 12 (01) : 1986 - 1996
  • [40] Promotion of Epithelial Healing in Oral Mucositis by hESC-Derived Mesenchymal Stem Cells via the PI3K/AKT Pathway
    Lv, Kejia
    Gao, Bicong
    Ye, Weijia
    Shen, Chenlu
    Chen, Tianchi
    Wang, Chaowei
    Yao, Hua
    CURRENT STEM CELL RESEARCH & THERAPY, 2024,